Hospital Formulary Status Yes (PO solid, PO powder for soln, parenteral inj)
In-Hospital Cost will be updated
PharmaCare Formulary Status Yes (PO solid, PO soln)
Special Authority Yes (PO solid) (See below under Restricted Use Criteria)
PharmaCare Coverage 50mg PO - $1.3936/tab 100mg PO - $2.4722/tab 150mg PO - $3.9303/cap 10mg/ml PO susp recon - $1.2955/ml
Outpatient Cost 50mg PO - $1.46-2.07/tab 100mg PO - $2.91-10.06/tab 150mg PO - $3.64-7.69/cap 10mg/ml PO susp recon - $1.30-1.42/ml 2mg/ml soln for inj - $0.51-0.56/ml
Candida infections both mucocutaneous and invasive - i.e. Candidemia.
Cryptococcus and Coccidioides infections.
Antifungal prophylaxis in immunocompromised.
Consider QTc monitoring if concomitant drugs affecting the interval or elevated baseline measurement.
Special Authority Status: Yes (PO solid)
Special Authority Category: Limited Coverage Drugs
Special Authority Criteria:
Special Authority Approval Period: One day to indefinite
Special Authority Practitioner Exemptions: Physicians specializing in treatment of HIV/AIDS patients
Special Authority Special Notes: None
Gastritis (PO and IV)
Hepatotoxicity (mainly with IV)
Alopecia (mainly with IV)
Chapped lips (mainly with IV)
Many via CYP450 - suggest review specific patient medications.
Fluconazole increases levels of phenytoin, cyclosporine, tacrolimus, warfarin, oral hypoglycemics.
Risk when combining with other QTc prolonging medications.
Antimicrobial class: Triazole Antifungal - decreases ergosterol synthesis
Pregnancy category: C
Average serum half life: 20.0 hr
Urine penetration: Therapeutic
Lung penetration: Therapeutic
CSF penetration: Therapeutic
Biliary penetration: Therapeutic